takeda pharmaceutical co ltd
(4502:Tokyo Stock Exchange)

Executive Profile*

Background*

Dr. Tadataka Yamada, Tachi, has been Corporate Officer and Head of Emerging Markets Commercial Operations for Nycomed A/S at Takeda Pharmaceutical Company Limited. Dr. Yamada served as an Executive Vice President and Medical and Scientific Advisor to the Chief Executive Officer of Takeda Pharmaceutical Company Limited. Dr. Yamada serves as an Executive Vice President and Medical and Scientific Advisor to the CEO at Takeda Pharmaceuticals International Inc. He was a Senior ... Executive in Residence at Frazier Healthcare Ventures until June 27, 2011. He joined Frazier Healthcare Ventures in 2006 and served in the biopharma team. In this capacity, he worked with both the growth equity and venture capital teams to create, identified and vet investment opportunities and in pursuing opportunities to launch and grow game-changing healthcare companies both in the United States and in emerging markets. He serves as Member of Scientific Advisory Board at VentiRx Pharmaceuticals, Inc. From 2006 to June 2011, Dr. Yamada served as the President of Global Health Program at Bill and Melinda Gates Foundation. In this role, he led the foundation’s efforts to help develop and deliver low cost, life saving health tools for the developing world. Dr. Yamada also oversaw the foundations global health grant portfolio and global health advocacy program. Prior to this, he served at GlaxoSmithkline Plc, where he served as the Chairman of Research and Development from February 1999 to June 2006, where he oversaw worldwide pharmaceutical research and development, and had been a Non Executive Director since February 1994. Dr. Yamada also served as the President and Executive Director of firm’s healthcare services from February 1996 to February 1999. From June 1990 to February 1996, he was the Chairman of the Department of Internal Medicine at the University of Michigan Medical School and Physician-in-Chief at the University of Michigan Medical Center. Dr. Yamada also served as a Professor and Chief of the Gastroenterology Division at the University of Michigan Medical School's Internal Medicine department. Prior to his work at the University of Michigan, he was an Associate Professor of Medicine at the UCLA School of Medicine. Dr. Yamada serves as a Director of Rockefeller Brothers Fund. He serves as a Director of Mallinckrodt Inc. and The Franklin Institute. Dr. Yamada serves as a Director of Covidien Ltd. He has been a Director of HLTH Corporation since May 1998 and Agilent Technologies Inc. since January 13, 2011. He serves as a Director and Member of Takeda Global Advisory Board of a Pharmaceutical Company Limited. He has been a Director of Takeda Pharmaceutical Company Limited since 2011. He serves as a Director of Takeda Pharmaceuticals International, Inc. and Agency for Science, Technology and Research. He served as a Director of WebMD Health Corp. He served as a Director of Covidien plc from June 29, 2007 to April 2011. He served as an Executive Director of GlaxoSmithkline Plc from January 01, 2004 to June 2006. He served as a Director of SmithKline Beecham Plc. Dr. Yamada previously served as a Director of diaDexus Inc. since September 1997. He served as a Director of Bioadvance. Dr. Yamada holds a B.A. in History from Stanford University and an M.D. from the New York University School of Medicine.

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
4502:JP	¥4,745.00 JPY	-55.00

COMPETITOR COMPENSATION